SEC filing · 8-K

Regeneron Pharmaceuticals, Inc.: Quarterly results

Regeneron amended its collaboration with Sanofi to co-develop four new antibodies, securing an upfront payment and resolving litigation.

Filed October 6, 2026

Positive for the company

What happened

Sanofi will make an upfront payment to Regeneron of $1.0 billion to co-develop four new antibodies.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Regeneron Pharmaceuticals, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.